CH Biotech R&D Co (TPE:6534) Other Current Payables: NT$145 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6534 CH Biotech R&D Co Ltd TPE:6534
84 GF Score
Price NT$93.70
GF Value NT$100.73
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is CH Biotech R&D Co Other Current Payables?

CH Biotech R&D Co TPE:6534 84 Other Current Payables is NT$145 Mil as of Dec. 2025. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.73 (Fairly Valued). The stock has 1 warning sign investors should review.

CH Biotech R&D Co's Other Current Payables for the quarter that ended in Dec. 2025 was NT$145 Mil.

CH Biotech R&D Co's quarterly Other Current Payables increased from Jun. 2025 (NT$122 Mil) to Sep. 2025 (NT$129 Mil) and increased from Sep. 2025 (NT$129 Mil) to Dec. 2025 (NT$145 Mil).

CH Biotech R&D Co's annual Other Current Payables increased from Dec. 2023 (NT$148 Mil) to Dec. 2024 (NT$159 Mil) but then declined from Dec. 2024 (NT$159 Mil) to Dec. 2025 (NT$145 Mil).

CH Biotech R&D Co Other Current Payables Related Terms

CH Biotech R&D Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for CH Biotech R&D Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CH Biotech R&D Co Other Current Payables Chart

CH Biotech R&D Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.95 117.00 147.70 159.11 145.22

CH Biotech R&D Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.11 481.77 121.94 128.72 145.22
TPE:6534
84GF Score
CH Biotech R&D Co Ltd TPE:6534
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CH Biotech R&D Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$145 Mil mean?
CH Biotech R&D Co (TPE:6534) has a Other Current Payables of NT$145 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on CH Biotech R&D Co and its competitors.
Is CH Biotech R&D Co's Other Current Payables too high?
CH Biotech R&D Co's current Other Current Payables is NT$145 Mil. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Other Current Payables compare to CTVA and CF?
CH Biotech R&D Co's Other Current Payables of NT$145 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for an Agriculture company?
A good Other Current Payables depends on the Agriculture industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current Other Current Payables is NT$145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Fairly Valued. The stock's GF Value™ is NT$100.73, compared to a current price of NT$93.70 — trading 7% below its estimated fair value. The current Other Current Payables is NT$145 Mil. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Other Current Payables is NT$145 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?

Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued. The current stock price of NT$93.70 is trading 7% below its estimated GF Value™ of NT$100.73. GuruFocus considers CH Biotech R&D Co to be Fairly Valued.

Key valuation signals for TPE:6534:

  • Other Current Payables: NT$145 Mil
  • GF Value™: NT$100.73 vs. price of NT$93.70 (7% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CH Biotech R&D Co Business Description

Address No. 89, Wenxian Road, Nantou County, Nantou City, TWN, 540001
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score

Get the complete analysis for TPE:6534

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$93.70
Price
NT$100.73
GF Value